Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly's 3Q Revenues up 18% | Contract Pharma

What are you searching for?

Sign in
Financial News

Lilly’s 3Q Revenues up 18%

COVID-19 antibodies sales were $217.1 million in the quarter.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lilly
3Q Revenues: $6.8 billion (+18%)
3Q Earnings: $1.1 billion (-8%)
YTD Revenues: $20.3 billion (+19%)
YTD Earnings: $3.9 billion (-5%)
Comments:  Key growth products, consisting of Trulicity, Taltz, Verzenio, Jardiance, Emgality, Olumiant, Tyvyt, Retevmo and Cyramza, contributed 17 percentage points of revenue growth and represented approximately 58 percent of total revenue in the third quarter, excluding revenue from COVID-19 therapies. COVID-19 antibodies sales were $217.1 million in the quarter. Revenue from Trulicity, Taltz, Verzenio and Emgality each grew by more than 30 percent versus prior year. Trulicity sales were $1.6 billion up 45% in the quarter. Humalog sales were down 5% to $626.7 million. Alimta sales were down 21% to $457 million. Taltz sales were $593.1 million, up 30%. Jardiance sales were $390.4 million, up 26%. Verzenio sales were $335.5 million, up 43%. Humulin sales were down 6% to $286.7 million. Olumiant sales reached $406.9 million.
 
Filings
The FDA approved Verzenio as the first and only CDK4/6 inhibitor for certain people with HR+ HER2- high risk early breast cancer.
 
The FDA approved a new indication for Erbitux in combination with Braftovi for the treatment of certain adult patients with metastatic colorectal cancer with a BRAF V600E mutation.
 
The FDA expanded the Emergency Use Authorization for bamlanivimab and etesevimab administered together to include post-exposure prophylaxis in certain individuals for the prevention of SARS-CoV-2 infection.
 
Jardiance was approved by the FDA to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters